THERAPY DOSSIER · th-efea9ca5deb8

N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23433551 ↗2013Reported benefit

Neutrophil-derived tumor necrosis factor-alpha contributes to acute wound healing promoted by N-(3-oxododecanoyl)-L-homoserine lactone from Pseudomonas aeruginosa.

RatWoundSprague-DawleyMaleApplied at the wound surface; anti-3-oxo-C12-HSL antiserum given intraperitoneally

Model: Full-thickness dorsal skin wounds inoculated with Pseudomonas aeruginosa strain PAO1 or its lasI deletion mutant

Inoculation with PAO1 significantly accelerated wound healing and the inflammatory response at day 3, an effect lost with the lasI mutant or with anti-3-oxo-C12-HSL antiserum. Administration of 3-oxo-C12-HSL alone promoted the same responses, and these were suppressed by anti-tumour necrosis factor…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…